OPKO Health, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
OPKO Health, Inc. (OPK) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of 0.70% for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-02.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2020-03-02
- OPKO Health, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2019 was 0.70%, a 75.86% decline from fiscal 2018.
- OPKO Health, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2018 was 2.90%, a 52.63% increase from fiscal 2017.
- OPKO Health, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2017 was 1.90%, a 0.00% change from fiscal 2016.
- OPKO Health, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2016 was 1.90%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month as first filed |
|---|---|---|
| 2019-12-31 | 0.70% 10-K · filed 2020-03-02 | |
| 2018-12-31 | 2.90% 10-K · filed 2020-03-02 | |
| 2017-12-31 | 1.90% 10-K · filed 2020-03-02 | |
| 2016-12-31 | 1.90% 10-K · filed 2019-03-01 | -1.90% 10-K · filed 2017-03-01 |
| 2015-12-31 | 0.70% 8-K · filed 2019-01-29 | -0.70% 10-K · filed 2017-03-01 |
| 2014-12-31 | 0.00% 10-K · filed 2017-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |